S100B as a new fecal biomarker of inflammatory bowel diseases

摘要: Objective S100 proteins are demonstrated to exert a protective role in the gastrointestinal tract. In present study, we investigated whether S100B protein, that is typically expressed by enteroglial cells, detectable feces and could be useful noninvasive indicator of gut chronic inflammation. Patients methods This clinical prospective study included n=48 patients suffering Crohn's disease (CD) or ulcerative colitis (UC) non IBD-controls. The activity was evaluated using Harvey-Bradshaw Mayo Score Index while diagnosis IBD defined based on standard endoscopic histological criteria. calprotectin were extracted analyzed commercial enzyme-linked immunosorbent assay (ELISA) kits. Results Unlike calprotectin, significantly decreased both CD UC compared IBD-patients. strongest quantitative alterations detected concomitantly with signs active quiescent disease, including high/normal expression fecal mucosal damage/cryptitis, mucin depletion inflammatory infiltrate, as evaluation analysis. At onset under no Infliximab-based therapy, lowest suggesting have potential diagnostic value for IBD. Conclusions Testing screening tool better predict activity.